CS 6253

Drug Profile

CS 6253

Alternative Names: Cogpep™; CS6253

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California at Berkeley
  • Developer Artery Therapeutics; Tel Aviv University; University of California at Berkeley
  • Class Neuropeptides
  • Mechanism of Action ATP binding cassette transporter 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Atherosclerosis; Type 2 diabetes mellitus

Most Recent Events

  • 30 Aug 2017 New profile created from abstract 3267616
  • 26 Aug 2017 Pharmacodynamics data from preclinical trials in Alzheimer's disease presented at the Annual Congress of the European Society of Cardiology (ESC Congress 2017)
  • 26 Aug 2017 Preclinical trials in Atherosclerosis in USA (SC) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top